259 related articles for article (PubMed ID: 18676758)
1. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.
Mackall CL; Rhee EH; Read EJ; Khuu HM; Leitman SF; Bernstein D; Tesso M; Long LM; Grindler D; Merino M; Kopp W; Tsokos M; Berzofsky JA; Helman LJ
Clin Cancer Res; 2008 Aug; 14(15):4850-8. PubMed ID: 18676758
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.
Merchant MS; Bernstein D; Amoako M; Baird K; Fleisher TA; Morre M; Steinberg SM; Sabatino M; Stroncek DF; Venkatasan AM; Wood BJ; Wright M; Zhang H; Mackall CL
Clin Cancer Res; 2016 Jul; 22(13):3182-91. PubMed ID: 26823601
[TBL] [Abstract][Full Text] [Related]
3. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.
Dagher R; Long LM; Read EJ; Leitman SF; Carter CS; Tsokos M; Goletz TJ; Avila N; Berzofsky JA; Helman LJ; Mackall CL
Med Pediatr Oncol; 2002 Mar; 38(3):158-64. PubMed ID: 11836714
[TBL] [Abstract][Full Text] [Related]
4. Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.
Ghisoli M; Barve M; Schneider R; Mennel R; Lenarsky C; Wallraven G; Pappen BO; LaNoue J; Kumar P; Nemunaitis D; Roth A; Nemunaitis J; Whiting S; Senzer N; Fletcher FA; Nemunaitis J
Mol Ther; 2015 Jun; 23(6):1103-1109. PubMed ID: 25917459
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors.
Suminoe A; Matsuzaki A; Hattori H; Koga Y; Hara T
Pediatr Transplant; 2009 Sep; 13(6):746-53. PubMed ID: 19067917
[TBL] [Abstract][Full Text] [Related]
6. Potential approaches to the treatment of Ewing's sarcoma.
Yu H; Ge Y; Guo L; Huang L
Oncotarget; 2017 Jan; 8(3):5523-5539. PubMed ID: 27740934
[TBL] [Abstract][Full Text] [Related]
7. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma.
Boulad F; Kernan NA; LaQuaglia MP; Heller G; Lindsley KL; Rosenfield NS; Abramson SJ; Gerald WL; Small TN; Gillio AP; Gulati SC; O'Reilly RJ; Ghavimi F
J Clin Oncol; 1998 May; 16(5):1697-706. PubMed ID: 9586881
[TBL] [Abstract][Full Text] [Related]
8. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.
Meyers PA; Krailo MD; Ladanyi M; Chan KW; Sailer SL; Dickman PS; Baker DL; Davis JH; Gerbing RB; Grovas A; Herzog CE; Lindsley KL; Liu-Mares W; Nachman JB; Sieger L; Wadman J; Gorlick RG
J Clin Oncol; 2001 Jun; 19(11):2812-20. PubMed ID: 11387352
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy.
Stea B; Kinsella TJ; Triche TJ; Horvath K; Glatstein E; Miser JS
Int J Radiat Oncol Biol Phys; 1987 Dec; 13(12):1797-805. PubMed ID: 3679916
[TBL] [Abstract][Full Text] [Related]
10. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
[TBL] [Abstract][Full Text] [Related]
11. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors.
Tanaka K; Matsunobu T; Sakamoto A; Matsuda S; Iwamoto Y
J Orthop Sci; 2002; 7(4):477-82. PubMed ID: 12181663
[TBL] [Abstract][Full Text] [Related]
14. Curability of Ewing's sarcoma and considerations for future therapeutic trials.
Rosen G; Caparros B; Mosende C; McCormick B; Huvos AG; Marcove RC
Cancer; 1978 Mar; 41(3):888-99. PubMed ID: 638976
[TBL] [Abstract][Full Text] [Related]
15. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
Czyzewski EA; Goldman S; Mundt AJ; Nachman J; Rubin C; Hallahan DE
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):569-77. PubMed ID: 10348286
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cell surface antigen HBA71 (p30/32MIC2), neuron-specific enolase, and vimentin in the immunohistochemical analysis of Ewing's sarcoma of bone.
Fellinger EJ; Garin-Chesa P; Glasser DB; Huvos AG; Rettig WJ
Am J Surg Pathol; 1992 Aug; 16(8):746-55. PubMed ID: 1497115
[TBL] [Abstract][Full Text] [Related]
17. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma.
Horowitz ME; Kinsella TJ; Wexler LH; Belasco J; Triche T; Tsokos M; Steinberg SM; McClure L; Longo DL; Steis RG
J Clin Oncol; 1993 Oct; 11(10):1911-8. PubMed ID: 8410118
[TBL] [Abstract][Full Text] [Related]
18. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study.
Evans RG; Nesbit ME; Gehan EA; Garnsey LA; Burgert O; Vietti TJ; Cangir A; Tefft M; Thomas P; Askin FB
J Clin Oncol; 1991 Jul; 9(7):1173-80. PubMed ID: 2045857
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy.
Mackall C; Berzofsky J; Helman LJ
Clin Orthop Relat Res; 2000 Apr; (373):25-31. PubMed ID: 10810459
[TBL] [Abstract][Full Text] [Related]
20. Oncological outcomes of patients with Ewing's sarcoma: is there a difference between skeletal and extra-skeletal Ewing's sarcoma?
Pradhan A; Grimer RJ; Spooner D; Peake D; Carter SR; Tillman RM; Abudu A; Jeys L
J Bone Joint Surg Br; 2011 Apr; 93(4):531-6. PubMed ID: 21464495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
